Our Unique PDK4 Strategy Performs Even When You Fall Asleep! !

The number of cycles administered was not restricted. Patients were treated until disease progression, unmanageable toxicity, death, or successful bridging to stem cell transplantation. Diagnosis of PTCL was confirmed by CPR in 120 out of 129 patients. Most patients suffered from PTCL, NOS (n=77, 64%). The remaining subtypes included AITL (n=22, 18%), ALCL (n=15, 13%), and others (n=6, 6%). The median age was 63 years (range, 29�C81 years). The median number of prior treatment lines was 2 (range, 1�C8). Previous CHOP/CHOP-like regimen had been given to 125 patients (96%). A total of 27 patients (21%) buy RGFP966 had undergone prior autoSCT and two patients (2%) had had an alloSCT. The median time from first diagnosis to study entry was 12 months and the median time from last disease progression to study entry was 1 month. Bone marrow involvement was seen in 30% of patients. The median number of cycles administered was two, and the median duration of treatment was 7 weeks. The main reasons for treatment discontinuation were progressive disease (n=82), death (n=14), patient decision (n=11), and adverse events (n=9). A total of 17 patients (13%) required dose reduction mainly to the first level of dose reduction (750 mg/m2). In terms of efficacy, 13 patients (11%) achieved a CR, 18 patients demonstrated a PR (15%), resulting in an ORR of 26%. In responding patients, the median time to response was 5.6 weeks (range, 4.3�C50.4 weeks). The median duration of response was 13.6 months (range, 4.5�C29.4 months). The median PFS and OS were 1.6 months and 7.9 months, respectively. Importantly, nine patients (7.5%) selleck chemical were able to proceed to stem cell transplantation. For the subgroup of patients (n=20) with a thrombocyte count PDK4 which seems to be somewhat superior to the results for the entire PTCL group. Table 1 summarizes the efficacy data of the two Phase II studies on belinostat.48 Table 1 Efficacy data for belinostat from Phase II studies Recently, a case report was published documenting high efficacy of belinostat in an elderly female patient with PTCL-NOS.49 After failing three different chemotherapy regimens, the patient was treated with belinostat and achieved a CR after two cycles. The patient received a total of 28 cycles and maintained a CR for 46 months. The patient relapsed 15 months after the last application of belinostat and died 3 months later due to progressive disease (personal communication).